Clusterin overexpression and relapse-free survival in breast cancer
- PMID: 19846927
Clusterin overexpression and relapse-free survival in breast cancer
Abstract
Background: The prognostic significance of the antiapoptotic protein secretory clusterin overexpression in breast cancer is unclear.
Patients and methods: Secretory clusterin expression was explained in three hundred and fifty-two patients with breast cancer by immunohistochemistry. Clusterin overexpression was tested for correlation with overall survival (OS) and relapse-free survival (RFS).
Results: The overall frequency of clusterin overexpression was 52% (178 out of 342) in breast cancer; 44% for in situ carcinomas and 53% for invasive cancer. Among fifty-six patients with tumor recurrence, clusterin overexpression was found in 74% (14 out of 19) in breast cancer <T2 stage and 51% (19 out of 37) in >or=T2 stage breast cancer. The Kaplan-Meier analysis revealed that clusterin overexpression was a prognostic factor for RFS in breast cancer <T2 stage (mean RFS, 79.8 vs. 73.5 months, p=0.044).
Conclusion: Our results suggest that clusterin overexpression might be a predictive factor for recurrence in <T2 stage breast cancer.
Similar articles
-
Prognostic significance of clusterin immunoreactivity in breast cancer.Neoplasma. 2007;54(1):46-50. Neoplasma. 2007. PMID: 17203891
-
Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.J Clin Oncol. 2009 Oct 1;27(28):4701-8. doi: 10.1200/JCO.2008.21.7075. Epub 2009 Aug 31. J Clin Oncol. 2009. PMID: 19720911 Clinical Trial.
-
Cyclin A and E2F1 overexpression correlate with reduced disease-free survival in node-negative breast cancer patients.Anticancer Res. 2006 Nov-Dec;26(6B):4415-21. Anticancer Res. 2006. PMID: 17201163
-
Circulating and disseminated tumor cells in the management of breast cancer.Am J Clin Pathol. 2009 Aug;132(2):237-45. doi: 10.1309/AJCPJI7DEOLKCS6F. Am J Clin Pathol. 2009. PMID: 19605818 Review.
-
Juvenile papillomatosis and breast cancer.J Surg Educ. 2007 Jul-Aug;64(4):234-6. doi: 10.1016/j.jsurg.2007.03.007. J Surg Educ. 2007. PMID: 17706578 Review. No abstract available.
Cited by
-
BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling.Nat Commun. 2022 Oct 31;13(1):6513. doi: 10.1038/s41467-022-34081-3. Nat Commun. 2022. PMID: 36316305 Free PMC article.
-
Aberrant fucosylation enables breast cancer clusterin to interact with dendritic cell-specific ICAM-grabbing non-integrin (DC-SIGN).Oncoimmunology. 2019 Jun 24;8(9):e1629257. doi: 10.1080/2162402X.2019.1629257. eCollection 2019. Oncoimmunology. 2019. PMID: 31428526 Free PMC article.
-
Overexpression of secretory clusterin (sCLU) induces chemotherapy resistance in human gastric cancer cells by targeting miR-195-5p.Bioengineered. 2020 Dec;11(1):472-483. doi: 10.1080/21655979.2020.1747825. Bioengineered. 2020. PMID: 32250192 Free PMC article.
-
Clusterin in Alzheimer's Disease: Mechanisms, Genetics, and Lessons From Other Pathologies.Front Neurosci. 2019 Feb 28;13:164. doi: 10.3389/fnins.2019.00164. eCollection 2019. Front Neurosci. 2019. PMID: 30872998 Free PMC article. Review.
-
Proteomics and its applications in breast cancer.Am J Cancer Res. 2021 Sep 15;11(9):4006-4049. eCollection 2021. Am J Cancer Res. 2021. PMID: 34659875 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
